Truncated aspartase enzyme derivatives and uses thereof

Abstract

Truncated derivatives of aspartase having enhanced catalytic activity and/or enhanced clot dissolution properties relative to native aspartase from E. coli. The enzymes are isolated by site-directed mutagenesis of DNA encoding aspartase. L-aspartic acid is manufactured by contacting fumarate and ammonium ion in the presence of an aspartase derivative.

Description

TECHNICAL FIELD

This invention generally relates to a family of novel derivatives of the aspartase enzyme. More particularly, the present invention relates to truncated derivatives of the aspartase enzyme.

BACKGROUND OF THE INVENTION

Aspartase (L-aspartate ammonia-lyase, E.C. 4.3.1.1) catalyzes the reversible deamination of L-aspartic acid to yield fumarate and ammonium ions (or salts). This dearnination reaction is represented by the Formula I: ##STR1##

Many plants and microorganisms produce aspartase to control various biological functions such as allowing microorganisms to grow by using glutamate as the only carbon source. The role of aspartase in this process is to recycle aspartic acid for the regeneration of oxaloacetate as an amino group acceptor.

Aspartase is a tetrameric protein with a subunit molecular weight of about 52,400 Da. Its amino acid sequence of aspartase derived from Escherichia coli (E. coli) has been reported by Takagi et al., Nucleic Acids Res. 13:2063 (1985), to be that described in SEQ ID NO: 1. The similar amino acid sequences of aspartase derived from other organisms have also been reported.

The gene that encodes aspartase, aspA, is a polynucleotide sequence of DNA consisting of approximately 1430 base pairs, including a ribosome binding region and a promoter region. The known sequence of this gene for E. coli is represented in SEQ ID NO: 1.

Aspartase is an allosteric enzyme having tvo structural conformations, a high activity form and a low activity forn. At pH values above neutrality, aspartase must be activated by aspartic acid and divalent metal ions in order to catalyze the addition of an ammonium ion across the double bond of fumarate.

Activation by nonspecific proteolytic cleavage of aspartase is also known. Yumoto et al., Biochim. Biophys. Acta 616:319 (1980) and Yumoto et al., Plysiol. Chem. Phys. 14:391 (1982), for example, have shown that non-specific proteolytic cleavage of peptide bonds near the C-terminal by several different proteases results in a several fold increase of aspartase activity. It was not clear from these studies, however, whether cleavage at a single site or multiple sites was responsible for the enhanced activity and if so, which ones.

It has been observed for the vast majority of enzymes, in contrast to the results observed with aspartase, that the removal of amino acids causes a decrease in the activity of the enzyme. As reported by Sala-Newby et al., Biochim. Biophys. Acta Protein Struct. MoL Enzymol. 1206:155 (1994), for example, the sequential removal of amino acids from the C-terminal of firefly luciferase leads to a stepwise loss of bioluminescent activity without regard to the nature or identity of the amino acid that is removed.

Aspartase is used commercially primarily to produce large quantities of L-aspartic acid. L-aspartic acid is used, for example, to produce polyaspartase for use in detergents and for the enhancement of nutrient absorption in agricultural applications. L-aspartic acid is also used for the manufacture of biodegradable chelating agents and in the food industry as a component of the artificial sweetener aspartame (NutraSweet.RTM.).

Development of a superior enzyme to produce L-aspartic acid faster, cheaper, or both would be a highly desirable improvement over the current art Currently, L-aspartic acid is commercially manufactured using a native or wild-type aspartase enzyme, such as that from E. coli. Heretofore, native aspartase was purified by chromatographic techniques, such as described by Karsten et al., Anal Biochemn. 147:336 (1985). Thus, there is a need to isolate and purify aspartase derivatives with enhanced catalytic activity that can produce as much aspartic acid in a given time with a lower quantity of enzyme.

Only recently has it been discovered that aspartase plays a role in blood clot dissolution. Sjostrom et al., Biochim Biophys. Acta 1324:182 (1997), found that a plasmninogen binding protein, identified as aspartase in this organism, stimulates the activation of plasminogen by tissue plasminogen activator (tPA). tPA is a new drug that has been approved for use in the treatment of heart attacks. This drug accelerates the dissolution of blood clots that lead to heart attacks and strokes. Thus, there is a need to isolate and purify derivatives of aspartase with an enhanced capability to aid in the dissolution of blood clots.

SUMMARY OF INVENTION

It is therefore an object of the present invention to provide an aspartase derivative that demonstrates enhanced catalytic activity in the production of L-aspartic acid.

It is another object to provide a purified form of an aspartase derivative with enhanced catalytic activity.

It is yet another object of the present invention to provide a derivative of aspartase that enhances blood clot dissolution.

It is still another object to provide a method of making an aspartase derivative with enhanced catalytic activity.

It is yet another object to provide a method for expressing and purifying an aspartase derivative.

It is an additional object of the present invention to provide a mutant aspA gene whose gene product is an aspartase derivative with enhanced catalytic activity.

It is still another object to provide a method for making a mutant aspA gene whose gene product is an aspartase derivative with enhanced catalytic activity.

At least one or more of the foregoing objects, together with the advantages thereof over the known art relating to aspartase derivatives, which shall become apparent from the specification which follows, are accomplished by the invention as hereinafter described and claimed.

In general the present invention provides an enzyme having enhanced catalytic activity, for the conversion of fumarate and ammonium ions to L-aspartic acid, relative to native aspartase from E. coli. The present invention also provides an enzyme that aids in blood clot dissolution.

The present invention also includes a method for preparing an aspartase derivative comprising the steps of providing a gene coding for a wild-type aspartase; inserting a stop codon at a position immediately following a codon encoding a positively charge amino acid of the wild-type aspartase, wherein the position of the amino acid is selected from the group consisting of 468, 470 and 471, thereby forming a mutant gene; expressing the mutant gene in an expression system, thereby producing the aspartase derivative; and, optionally, purifying the aspartase derivative.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the carboxy-terminal sequence of aspartase with the truncation sites indicated with a (.dwnarw.)

FIG. 2 shows the relationship of the kinetic parameters of aspartase to the identity and position of the carboxy-terminal amino acid. The K.sub.m values of the truncation mutants (.cndot.) are shown along with the associated standard errors, and the catalytic activity of the mutants (% k.sub.cat) are compared in a bar graph to the activity of the native enzyme.

PREFERRED EMBODIMENT FOR CARRYING OUT THE INVENTION

It has now been found that derivatives of the aspartase enzyme exhibit improved properties over those properties associated with the native or wild-type aspartase enzyme. The expression of these novel enzymes is possible by using recombinant DNA technology. An expression vector, such as pTZ18R, can incorporate the gene that encodes for aspartase using well known restriction enzyme digestion and ligation techniques. Multiple copies of this recombinant expression vector can be introduced into a strain of E. coli to generate an overproducing strain that serves as the source for the crude aspartase enzyme.

The novel enzymes of the present invention are similar in structure to the native aspartase enzyme of E. coli, the sequence of which is shown in SEQ ID NO: 1, but which have at least one amino acid deleted from the C-terminal end. These derivatives will be referred to as truncated aspartase or aspartase mutants. In the preferred embodiments of the present invention, the truncated enzymes contain at least the first 468 residues of native aspartase.

One preferred embodiment of the present invention is a derivative of aspartase that has been truncated by deleting 7 amino acids from the C-terminal end. Using standard nomenclature, this enzyme will be referred to as Y472stop. The sequence of this truncated enzyme is represented by residues 1-471 of SEQ ID NO: 1.

It has surprisingly been found that the catalytic activity of this enzyme is increased to greater than 100%, preferably to at least about 150%, and even more preferably to at least about 200% of the catalytic activity of native aspartase. By catalytic activity it is meant that the enzyme is capable of catalyzing, in the presence of a substrate and metal ions at pH values above neutrality, the formation of L-aspartic acid from fumarate and ammonium ions.

Typically, the catalytic activity is determined spectrophotometrically and is reported by its rate constant, k.sub.cat, which is the number of molecules of substrate converted to product per unit time. Preferably, the catalytic activity of the truncated form and the native form are measured in simultaneously run assays under identical conditions in order to avoid assay-to-assay variations in activity by virtue of slight differences in the assay conditions. The effectiveness of a particular mutant enzyme is also reflected in its affinity for substrates as measured by its Michaelis constant, K.sub.M, which is the concentration of substrate that gives half maximal reaction velocity. A higher affinity results in a higher effective concentration of the substrate.

Another embodiment of the present invention is directed toward a truncated aspartase enzyme that has 8 amino acids deleted from the C-terminal end of the native enzyme. The sequence of this particular enzyme, which will be referred to hereinafter as R471stop, is represented by residues 1-470 of SEQ ID NO: 1.

As with the Y472stop enzyme, the R471stop enzyme shows increased catalytic activity. Particularly, the catalytic activity of the R471stop enzyme is greater than 100%, preferably at least about 125%, and more preferably at least about 150% of the catalytic activity of native aspartase.

Another embodiment of the present invention is directed toward a truncated aspartase enzyme that has 5 amino acids deleted from the C-terminal end of the native enzyme. The sequence of this particular enzyme, which will be referred to hereinafter as D474stop, is represented by residues 1-473 of SEQ ID NO: 1. The catalytic activity of the D474stop enzyme is greater than 100% of the catalytic activity of native aspartase.

Yet another embodiment of the present invention is directed toward a truncated aspartase derivative that has 10 amino acids deleted from the C-terminal end. This enzyme, which will be referred to hereinafter as A469stop, is represented by residues 1-468 of SEQ ID NO: 1.

Surprisingly, this particular truncated aspartase enzyme has demonstrated the potential for enhanced clot dissolution properties that are not present in the native aspartase enzyme from E. Coli. Without intending to be bound by any particular theory, it is believed that the A469stop enzyme demonstrates its clot dissolution properties by promoting the activation of plasminogen to plasmin by tissue plasminogen activator (tPA) by binding to plasminogen or to tPA more effectively than the native aspartase enzyme. The resulting activated plasmin will catalytically degrade the fibrin deposits leading to the dissolution of the blood clot. According to the method of Jones et al., Thrombosis and Haemostasis 64:455 (1990), which is incorporated herein by reference, activation of plasminogen by tPA shows a dose dependent response in the presence of increasing concentrations of the A469stop mutant enzyme. Promotion of this activation is not observed with native aspartase from E. coli.

Also encompassed by the invention is any analog of the truncated aspartase enzymes disclosed herein. In accordance with this invention, the term analog includes an enzyme having amino acid substitutions, additions or deletions that do not eliminate the enzymatic activity of the truncated enzymes disclosed herein. Preferably, the analogs encompassed herein will retain at least about 100%, preferably at least about 150% and even more preferably at least about 200% of the catalytic activity of the truncated enzyme.

Skilled artisans will readily appreciate that an analog of the truncated enzymes disclosed herein can be readily constructed. The analog can be prepared, for example, by exploiting the degeneracy in the genetic code, or by effecting a point mutation that yields an amino acid substitution and/or addition or deletion of non-essential amino acids.

By way of example, an analog preferably includes those proteins having at least about 50%, preferably at least about 85%, and more preferably at least about 90% amino acid homology. In addition, these enzymes all contain the signature amino acid sequence of aspartase-related enzymes. This sequence is known to be Gly-Ser-Ser-Ile-Met-Pro-Ala-Lys. Therefore, these enzymes still possess substantially similar enzymatic activity as that of the truncated enzymes disclosed herein.

Additional embodiments of this invention include DNA molecules that encode the proteins described herein. These DNA molecules are represented in SEQ ID NO: 2. Specifically, Y472stop is encoded by nucleotides 575-1987; R471stop is encoded by nucleotides 575-1984; D474stop is encoded by nucleotides 575-1993; A469stop is encoded by nucleotides 575-1978.

Those skilled in the art will appreciate that, based on the redundancy in the genetic code, many different DNA molecules can encode a single protein, and preferred codons can be employed for any given expression system. Furthermore, although derivatives of E. coli aspartase and the corresponding DNA sequences are preferred embodiments of the present invention, skilled artisans will realize that derivatives of aspartase derived from the DNA of other organisms may have amino acid substitutions, additions, deletions, or a combination thereof due to slight differences in the DNA sequences among organisms. All such DNA molecules are contemplated within this invention.

The aspartase derivatives of the present invention are obtained by the expression of a mutated form of the aspA gene that encodes aspartase. Charged or polar amino acids were sequentially eliminated from the carboxy terminal end by introducing stop codons at specific positions in the C-terminal region using site-directed mutagenesis techniques such as those described in White (Ed.), PCR Protocols: Current Methods and Applications (1993), which is incorporated herein by reference.

In order to obtain a protein or other gene product from a gene, living cells can be used to express the protein. This is commonly done using a plasmid vector into which the altered gene is inserted. The recombinant plasmid is then taken up by a bacterium, preferably from the TG-1 or JRG-1476 E. coli cell line, and the bacterium is then permitted to reproduce in large quantities as described by Guest et al., J. Gen. Microbiol. 130:1271 (1984), which is incorporated herein by reference. These transformed bacteria then express the protein in sufficient amount for purification. All of these steps of getting a gene product from a gene are well known.

The following examples merely illustrate the invention and, as such, are not to be considered as limiting the invention set forth in the claims.

GENERAL EXPERIMENTATION

EXAMPLE 1

Production and Expression of Truncated Aspartase in E. coli

The aspA gene from E. coli that encodes aspartase was inserted into a pTZ18R expression vector by cutting the vector at unique KpnI and HindIII restriction sites using well known digestion and ligation techniques, such as those described by Saribas et al., J. of Biol. Chem. 269:6313 (1994), incorporated herein by reference. Subsequent site-directed mutagenesis was carried out by using the recombinant circle PCR (RC-PCR) method described by Tarragona-Fiol et al., Protein Eng. 6:901 (1993), incorporated herein by reference. This method requires four primers, Le., single-stranded oligonuclotides that are synthesized to contain a mutation. Primers are incubated in pairs such that a mismatch of two to three base pairs is produced.

Alternatively, site-directed mutagenesis was carried out using the method of Kunkel et al., Methods Enzymol. 154:367 (1987). This method involves the replacement of thymine with uracil in the wild type strand of DNA. The subsequent destruction of the uracil-containing strand after heteroduplex formation leads to high yields of mutants.

The primers generate stop codons and alter the restriction enzyme sites at the loci of mutation, positions 467, 469, 471, 472, and 474 of the corresponding protein. The mutation at position 469 destroys a BspWI site; the mutations at 471 and 472 create an AccI site, but the mutation at 472 required the creation of a silent mutation at residue 471 because a restriction enzyme site could not be created at the mutation site; and the mutations at positions 467 and 474 create an AflII site. These alterations in the restriction enzyme sites are necessary to facilitate screening of the colonies to locate and identify the presence of these mutations by restriction enzyme analysis.

Gene amplification of the mutated genes was optimized using a twelve buffer optimization kit (Opti-Prime) that varied the sensitive parameters, including [Mg.sup.2+ ], [K.sup.+ ] and pH. Polymerase chain reaction (PCR) amplification was carried out using native pfu DNA polymerase for its proofreading ability, and for producing less contamination than either recombinant pfu or tac polymerases. Thin wall tubes were used for effective heat transfer during the thermocycliryg steps. Standard multicycle gene amplification was carried out using techniques similar to these described in U.S. Pat. Nos. 4,683,195 and 4,683,202, which are incorporated herein by reference.

Double-stranded DNA molecules with discrete, cohesive, single-stranded ends were synthesized and analyzed on an agarose gel to determine the optimum conditions for their formation. The products were then extracted from the gel before being recombined to produce recombinant circles in a buffer containing 10 mM Tris-HCl, pH 8.8, 10 mM NaCl and 1 mM EDTA. Denaturing was then performed at 92.degree. C. for 5 minutes before being reannealed for 3 hours at 57.degree. C.

The DNA was then in condition for transformation. The recombinant circle DNA molecules were incubated with competent cells for 1.5 hours and heat shocked at 42.degree. C. for 1.5 minutes. The cells were then kept on ice for 5 minutes before being plated on YT agar plates containing ampicillin. The presence of mutagenic colonies was screened using restriction enzyme mapping, and the mutated region of the DNA of these colonies was sequenced.

EXAMPLE 2

Characterization and Purification of the Bacterially Expressed Truncated Aspartase

The C-terminal of each aspartase derivative is shown in FIG. 1 as a theoretical cleavage of native aspartase. All of the derivatives, except the Y467 mutant, were purified by the procedure described by Karsten et al., Anal. Biochem. 147:336 (1985), from an overproducing strain of E. coli developed and described by Saribas et al., J. Biol. Chem. 269:6313 (1994), both methods being incorporated herein by reference. Due to the low affinity of the Y467 mutant for red-A agarose column used in the published procedure, a similar, modified procedure described by Saribas in his Ph.D. thesis (University of Akron, 1992), incorporated herein by reference, uses a KCl gradient elution from DEAE-sepharose and a Sephacryl-300 gel filtration step.

Catalytic activity was determined spectrophotometrically by measuring the formation of fumarate at 240 nm (E.sub.240 =2.53 mM.sup.-1 cm.sup.-) produced by the enzyme-catalyzed deamination of aspartic acid. A standard assay mix contained 30 mM Hepes buffer, pH 7.0, 10 mM magnesium acetate, and varying concentrations of L-aspartic acid at 30.degree. C. The activity of each mutant was then reported as k.sub.cat and the affinity for the substrate as K.sub.M (Table I), as shown in FIG. 2 and Table I.

TABLE I______________________________________Kinetic Parameters of Truncated Derivatives of Aspartase Enhanced per- Clotenzyme k.sub.cat cent Dissolu-mutant (min.sup.-1) k.sub.cat K.sub.M (mM) k.sub.cat /K.sub.M tion______________________________________Wild-type 40.5 .+-. 1.6 100 1.8 .+-. 0.1 22.6 .+-. 0.9 --D474stop 42.7 .+-. 7.6 105 2.8 .+-. 1.1 15.3 .+-. 2.9 --Y472stop 97.2 .+-. 6.1 240 3.3 .+-. 0.8 29.5 .+-. 1.8 --R471stop 70.7 .+-. 2.9 175 4.5 .+-. 0.5 15.7 .+-. 0.6 --A469stop 39.6 .+-. 1.0 98 10.2 .+-. 0.7 3.9 .+-. 0.1 yesY467stop 2.5 .+-. 0.8 6.1 31 .+-. 8.2 0.08 .+-. 0.003 --______________________________________

Based upon the foregoing disclosure, it should now be apparent that the use of the enzymes described herein will carry out the objects set forth hereinabove. It is therefore to be understood that any variations evident fall within the scope of the claimed invention. In particular, other means for isolating and purifying the enzymes can be substituted for the techniques described hereinabove. Thus, the scope of the invention shall include all modifications and variations that may fall within the scope of the attached claims.

SEQUENCE LISTINGS

Amino and nucleic acid Sequence of the Sequence Listings are identified as follows:

(a) SEQ ID NO: 1 shows the amino acid sequence of the native aspartase enzyme of E. coli. (b) SEQ ID NO: 2 shows the nucleotide sequence of E. coli in the region containing the aspartase gene. __________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 2- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 478 ami - #no acids (B) TYPE: amino aci - #d (C) STRANDEDNESS: sing - #le (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein no (iii) HYPOTHETICAL: no (iv) ANTI-SENSE:- (vi) ORIGINAL SOURCE: (A) ORGANISM: Escheric - #hia coli# K12 (C) INDIVIDUAL ISOLATE: (G) CELL TYPE: unic - #ellular organism- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- Met Ser Asn Asn Ile Arg Ile Glu Glu Asp Le - #u Leu Gly Thr Arg Glu# 15- Val Pro Ala Asp Ala Tyr Tyr Gly Val His Th - #r Leu Arg Ala Ile Val# 30- Asn Phe Tyr Ile Ser Asn Asn Lys Ile Ser As - #p Ile Pro Glu Phe Val# 45- Arg Gly Met Val Met Val Lys Lys Ala Ala Al - #a Met Ala Asn Lys Glu# 60- Leu Gln Thr Ile Pro Lys Ser Val Ala Asn Al - #a Ile Ile Ala Ala Cys# 80- Asp Glu Val Leu Asn Asn Gly Lys Cys Met As - #p Gln Phe Pro Val Asp# 95- Val Tyr Gln Gly Gly Ala Gly Thr Ser Val As - #n Met Asn Thr Asn Glu# 110- Val Leu Ala Asn Ile Gly Leu Glu Leu Met Gl - #y His Gln Lys Gly Glu115 1 - #20 1 - #25- Tyr Gln Tyr Leu Asn Pro Asn Asp His Val As - #n Lys Cys Gln Ser Thr# 140- Asn Asp Ala Tyr Pro Thr Gly Phe Arg Ile Al - #a Val Tyr Ser Ser Leu145 1 - #50 1 - #55 1 -#60- Ile Lys Leu Val Asp Ala Ile Asn Gln Leu Ar - #g Glu Gly Phe Glu Arg165 1 - #70 1 - #75- Lys Ala Val Glu Phe Gln Asp Ile Leu Lys Me - #t Gly Arg Thr Gln Leu# 190- Gln Asp Ala Val Pro Met Thr Leu Gly Gln Gl - #u Phe Arg Ala Phe Ser195 2 - #00 2 - #05- Ile Leu Leu Lys Glu Glu Val Lys Asn Ile Gl - #n Arg Thr Ala Glu Leu# 220- Leu Leu Glu Val Asn Leu Gly Ala Thr Ala Il - #e Gly Thr Gly Leu Asn225 2 - #30 2 - #35 2 -#40- Thr Pro Lys Glu Tyr Ser Pro Leu Ala Val Ly - #s Lys Leu Ala Glu Val245 2 - #50 2 - #55- Thr Gly Phe Pro Cys Val Pro Ala Glu Asp Le - #u Ile Glu Ala Thr Ser# 270- Asp Cys Gly Ala Tyr Val Met Val His Gly Al - #a Leu Lys Arg Leu Ala275 2 - #80 2 - #85- Val Lys Met Ser Lys Ile Cys Asn Asp Leu Ar - #g Leu Leu Ser Ser Gly# 300- Pro Arg Ala Gly Leu Asn Glu Ile Asn Leu Pr - #o Glu Leu Gln Ala Gly305 3 - #10 3 - #15 3 -#20- Ser Ser Ile Met Pro Ala Lys Val Asn Pro Va - #l Val Pro Glu Val Val325 3 - #30 3 - #35- Asn Gln Val Cys Phe Lys Val Ile Gly Asn As - #p Thr Thr Val Thr Met# 350- Ala Ala Glu Ala Gly Gln Leu Gln Leu Asn Va - #l Met Glu Pro Val Ile355 3 - #60 3 - #65- Gly Gln Ala Met Phe Glu Ser Val His Ile Le - #u Thr Asn Ala Cys Tyr# 380- Asn Leu Leu Glu Lys Cys Ile Asn Gly Ile Th - #r Ala Asn Lys Glu Val385 3 - #90 3 - #95 4 -#00- Cys Glu Gly Tyr Val Tyr Asn Ser Ile Gly Il - #e Val Thr Tyr Leu Asn405 4 - #10 4 - #15- Pro Phe Ile Gly His His Asn Gly Asp Ile Va - #l Gly Lys Ile Cys Ala# 430- Glu Thr Gly Lys Ser Val Arg Glu Val Val Le - #u Glu Arg Gly Leu Leu435 4 - #40 4 - #45- Thr Glu Ala Glu Leu Asp Asp Ile Phe Ser Va - #l Gln Asn Leu Met His# 460- Pro Ala Tyr Lys Ala Lys Arg Tyr Thr Asp Gl - #u Ser Glu Gln465 4 - #70 4 - #75- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2280 bp (B) TYPE: nucleic a - #cid (C) STRANDEDNESS: sing - #le (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: genomic DNA no (iii) HYPOTHETICAL: no (iv) ANTI-SENSE:- (vi) ORIGINAL SOURCE: (A) ORGANISM: Escheric - #hia coli# K12 (C) INDIVIDUAL ISOLATE: (G) CELL TYPE: unic - #ellular organism- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- TGATCAGCGA AACACTTTTA ATCATCTCCG CCGCTGGGTT TTCACCCGCC GC - #CATTTTTT 60- GCTGCATCAG CACGAAATTC TTAAAGCCCT GGTTACGTAC CAGTGACATA CC - #GATAACTG 120- ACGTGAATAT AACCAGCACG AGGGTCAGCA ATACCCCCAA TACATGGGCA AC - #CTGAATAA 180- AGATTGAAAT CTCAATATAG ACATAAAGGA AAATGGCAAT AAAAGGTAAC CA - #GCGCAAAG 240- GTTTCTCCTG TAATAGCAGC CGGTTAACCC CGGCTACCTG AATGGGTTGC GA - #ATCGCGTT 300- TAGCTTATAT TGTGGTCATT AGCAAAATTT CAAGATGTTT GCGCAACTAT TT - #TTGGTAGT 360- AATCCCAAAG CGGTGATCTA TTTCACAAAT TAATAATTAA GGGGTAAAAA CC - #GACACTTA 420- AAGTGATCCA GATTACGGTA GAAATCCTCA AGCAGCATAT GATCTCGGGT AT - #TCGGTCGA 480- TGCAGGGGAT AATCGTCGGT CGAAAAACAT TCGAAACCAC ATATATTCTG TG - #TGTTTAAA 540- GCAAATCATT GGCAGCTTGA AAAAGAAGGT TCAC ATG TCA AAC A - #AC ATT CGT ATC 595# Met Ser Asn Asn Ile Arg Ile#5 1- GAA GAA GAT CTG TTG GGT ACC AGG GAA GTT CC - #A GCT GAT GCC TAC TAT 643Glu Glu Asp Leu Leu Gly Thr Arg Glu Val Pr - #o Ala Asp Ala Tyr Tyr# 20- GGT GTT CAC ACT CTG AGA GCG ATT GTA AAC TT - #C TAT ATC AGC AAC AAC 691Gly Val His Thr Leu Arg Ala Ile Val Asn Ph - #e Tyr Ile Ser Asn Asn# 35- AAA ATC AGT GAT ATT CCT GAA TTT GTT CGC GG - #T ATG GTA ATG GTT AAA 739Lys Ile Ser Asp Ile Pro Glu Phe Val Arg Gl - #y Met Val Met Val Lys# 55- AAA GCC GCA GCT ATG GCA AAC AAA GAG CTG CA - #A ACC ATT CCT AAA AGT 787Lys Ala Ala Ala Met Ala Asn Lys Glu Leu Gl - #n Thr Ile Pro Lys Ser# 70- GTA GCG AAT GCC ATC ATT GCC GCA TGT GAT GA - #A GTC CTG AAC AAC GGA 835Val Ala Asn Ala Ile Ile Ala Ala Cys Asp Gl - #u Val Leu Asn Asn Gly# 85- AAA TGC ATG GAT CAG TTC CCG GTA GAC GTC TA - #C CAG GGC GGC GCA GGT 883Lys Cys Met Asp Gln Phe Pro Val Asp Val Ty - #r Gln Gly Gly Ala Gly#100- ACT TCC GTA AAC ATG AAC ACC AAC GAA GTG CT - #G GCC AAT ATC GGT CTG 931Thr Ser Val Asn Met Asn Thr Asn Glu Val Le - #u Ala Asn Ile Gly Leu# 115- GAA CTG ATG GGT CAC CAA AAA GGT GAA TAT CA - #G TAC CTG AAC CCG AAC 979Glu Leu Met Gly His Gln Lys Gly Glu Tyr Gl - #n Tyr Leu Asn Pro Asn120 1 - #25 1 - #30 1 -#35- GAC CAT GTT AAC AAA TGT CAG TCC ACT AAC GA - #C GCC TAC CCG ACC GGT1027Asp His Val Asn Lys Cys Gln Ser Thr Asn As - #p Ala Tyr Pro Thr Gly140 1 - #45 1 - #50- TTC CGT ATC GCA GTT TAC TCT TCC CTG ATT AA - #G CTG GTA GAT GCG ATT1075Phe Arg Ile Ala Val Tyr Ser Ser Leu Ile Ly - #s Leu Val Asp Ala Ile# 165- AAC CAA CTG CGT GAA GGC TTT GAA CGT AAA GC - #T GTC GAA TTC CAG GAC1123Asn Gln Leu Arg Glu Gly Phe Glu Arg Lys Al - #a Val Glu Phe Gln Asp170 1 - #75 1 - #80- ATC CTG AAA ATG GGT CGT ACC CAG CTG CAG GA - #C GCA GTA CCG ATG ACC1171Ile Leu Lys Met Gly Arg Thr Gln Leu Gln As - #p Ala Val Pro Met Thr# 195- CTC GGT CAG GAA TTC CGC GCT TTC AGC ATC CT - #G CTG AAA GAA GAA GTG1219Leu Gly Gln Glu Phe Arg Ala Phe Ser Ile Le - #u Leu Lys Glu Glu Val200 2 - #05 2 - #10 2 -#15- AAA AAC ATC CAA CGT ACC GCT GAA CTG CTG CT - #G GAA GTT AAC CTT GGT1267Lys Asn Ile Gln Arg Thr Ala Glu Leu Leu Le - #u Glu Val Asn Leu Gly220 2 - #25 2 - #30- GCA ACA GCA ATC GGT ACT GGT CTG AAC ACG CC - #G AAA GAG TAC TCT CCG1315Ala Thr Ala Ile Gly Thr Gly Leu Asn Thr Pr - #o Lys Glu Tyr Ser Pro# 245- CTG GCA GTG AAA AAA CTG GCT GAA GTT ACT GG - #C TTC CCA TGC GTA CCG1363Leu Ala Val Lys Lys Leu Ala Glu Val Thr Gl - #y Phe Pro Cys Val Pro250 2 - #55 2 - #60- GCT GAA GAC CTG ATC GAA GCG ACC TCT GAC TG - #C GGC GCT TAT GTT ATG1411Ala Glu Asp Leu Ile Glu Ala Thr Ser Asp Cy - #s Gly Ala Tyr Val Met# 275- GTT CAC GGC GCG CTG AAA CGC CTG GCT GTG AA - #G ATG TCC AAA ATC TGT1459Val His Gly Ala Leu Lys Arg Leu Ala Val Ly - #s Met Ser Lys Ile Cys280 2 - #85 2 - #90 2 -#95- AAC GAC CTG CGC TTG CTC TCT TCA GGC CCA CG - #T GCC GGC CTG AAC GAG1507Asn Asp Leu Arg Leu Leu Ser Ser Gly Pro Ar - #g Ala Gly Leu Asn Glu300 3 - #05 3 - #10- ATC AAC CTG CCG GAA CTG CAG GCG GGC TCT TC - #C ATC ATG CCA GCT AAA1555Ile Asn Leu Pro Glu Leu Gln Ala Gly Ser Se - #r Ile Met Pro Ala Lys# 325- GTA AAC CCG GTT GTT CCG GAA GTG GTT AAC CA - #G GTA TGC TTC AAA GTC1603Val Asn Pro Val Val Pro Glu Val Val Asn Gl - #n Val Cys Phe Lys Val330 3 - #35 3 - #40- ATC GGT AAC GAC ACC ACT GTT ACC ATG GCA GC - #A GAA GCA GGT CAG CTG1651Ile Gly Asn Asp Thr Thr Val Thr Met Ala Al - #a Glu Ala Gly Gln Leu# 355- CAG TTG AAC GTT ATG GAG CCG GTC ATT GGC CA - #G GCC ATG TTC GAA TCC1699Gln Leu Asn Val Met Glu Pro Val Ile Gly Gl - #n Ala Met Phe Glu Ser360 3 - #65 3 - #70 3 -#75- GTT CAC ATT CTG ACC AAC GCT TGC TAC AAC CT - #G CTG GAA AAA TGC ATT1747Val His Ile Leu Thr Asn Ala Cys Tyr Asn Le - #u Leu Glu Lys Cys Ile380 3 - #85 3 - #90- AAC GGC ATC ACT GCT AAC AAA GAA GTG TGC GA - #A GGT TAC GTT TAC AAC1795Asn Gly Ile Thr Ala Asn Lys Glu Val Cys Gl - #u Gly Tyr Val Tyr Asn# 405- TCT ATC GGT ATC GTT ACT TAC CTG AAC CCG TT - #C ATC GGT CAC CAC AAC1843Ser Ile Gly Ile Val Thr Tyr Leu Asn Pro Ph - #e Ile Gly His His Asn410 4 - #15 4 - #20- GGT GAC ATC GTG GGT AAA ATC TGT GCC GAA AC - #C GGT AAG AGT GTA CGT1891Gly Asp Ile Val Gly Lys Ile Cys Ala Glu Th - #r Gly Lys Ser Val Arg# 455- GAA GTC GTT CTG GAA CGC GGT CTG TTG ACT GA - #A GCG GAA CTT GAC GAT1939Glu Val Val Leu Glu Arg Gly Leu Leu Thr Gl - #u Ala Glu Leu Asp Asp440 4 - #45 4 - #50 4 -#55- ATT TTC TCC GTA CAG AAT CTG ATG CAC CCG GC - #T TAC AAA GCA AAA CGC1987Ile Phe Ser Val Gln Asn Leu Met His Pro Al - #a Tyr Lys Ala Lys Arg460 4 - #65 4 - #70- TAT ACT GAT GAA AGC GAA CAG TAATCGTACA GGGTAGTAC - #A AATAAAAAAG2038Tyr Thr Asp Glu Ser Glu Gln 475- GCACGTCAGA TGACGTGCCT TTTTTCTTGT GAGCAGTAAC TTAAAAATAA CA - #ATCTAATA2098- TCAACTTGTT AAAAAACAAG GAAGGCTAAT ATGCTAGTTG TAGAACTCAT CA - #TAGTTTTG2158- CTGGCGATCT TCTTGGGCGC CAGATTGGGG GGAATAGGTA TTGGTTTTGC AG - #GCGGATTG2218- GGGGTGCTGG TTCTTGCCGC TATTGGCGTT AAACCCGGTA ACATCCCGTT CG - #ATGTCATC2278# 2280__________________________________________________________________________

Claims

1. An enzmye consisting of a truncated E. coli aspartase having an amino acid sequence represented by residues 1-468 of SEQ ID NO: 1.

2. The enzyme of claim 1, wherein the enzyme has enhanced clot dissolution capabilities relative to native aspartase from E. coli.

3. A method for dissolving a blood clot comprising the step of adding an aspartase derivative to plasminogen and tissue plasminogen activator, thereby enhancing the production of plasmin and enhancing dissolution of the blood clot, wherein said truncated E. coli aspartase derivative consists of the amino acid sequence represented by residues 1-468 of SEQ ID NO: 1.

4. A pharmaceutical composition containing the truncated E. coli aspartase derivative of claim 1.